1 / 19

PCSK9 Mutations

PCSK9 Mutations. PCSK9 Loss-of-function Mutations. 2013 ACC/AHA Cholesterol Guidelines 4 Major Statin Benefit Groups. PCSK9 Monoclonal Antibodies. MENDEL Evolocumab Monotherapy for H ypercholesterolemia. LAPLACE-2 Study Design. LAPLACE-2 LDL-C Response at Mean of Weeks 10 and 12.

tashya-shepherd
Télécharger la présentation

PCSK9 Mutations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PCSK9 Mutations

  2. PCSK9 Loss-of-function Mutations

  3. 2013 ACC/AHA Cholesterol Guidelines4 Major Statin Benefit Groups

  4. PCSK9 Monoclonal Antibodies

  5. MENDELEvolocumab Monotherapy for Hypercholesterolemia

  6. LAPLACE-2Study Design

  7. LAPLACE-2LDL-C Response at Mean of Weeks 10 and 12

  8. GAUSS-2Percent Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients

  9. DESCARTESPercent Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia

  10. DESCARTES Evolocumab Safety at 52 weeks

  11. PCSK9 CV OutcomesTrials

  12. Abbreviations

  13. Abbreviations (cont)

  14. References

  15. References (cont)

  16. References (cont)

More Related